Heart Attack No Longer the Leading Cause of Death in America . Journal of AHA reports that heart disease mortality in the United States dropped by 66 percent over the past five decades, driven largely by a dramatic decline in fatal heart attacks. https://t.co/whMQSMozVv https://t.co/ik6uydmspF

• Mortalities from America's top cause of death have dropped 66 percent—Study

Systemic immune-inflammation index (SII), as a potential biomarker -- computed as platelet count × neutrophil count/lymphocyte count. SII has been shown to be useful in RA, PsA, SpA, SLE and vasculitis, reflecting disease activity, drug responses & supplements ESR & CRP levels https://t.co/LuFaYbWiWN

Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4

• https://buff.ly/CmX7hU6

MTX or TNFi use in elderly #RA pts w/in a year of Dx of melanoma was not associated with increased mortality. This included melanoma in situ (48%), localized (47%) and regional (5%) melanoma. Steroid use however was assoc w/ reduced survival. https://t.co/QOXfEf51S1 https://t.co/6BPtEV6sOU

• https://buff.ly/K94RJtT

FDA is evaluating the safety of Vyvgart Hytrulo, ((efgartigimod) used to treat AChR Ab positive generalized myasthenia gravis (gMG). But in clinical trials there are reports of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)” https://t.co/6GBwIJ4ig4

Osteoporosis Drug May Lower Osteoarthritis Risk A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. https://t.co/fWWw2t2jzR

PMR & GCA not assoc w/ increased mortality, Norway study of 274 isolated PMR (mean age 72 yrs) & 63 GCA (age 72 yrs) pts. After mean F/U 13.7 yrs 96% were deceased. Standardized mortality ratio was Not incr for PMR (0.97)or GCA (1.10), but men w/ PMR had , lower all-cause https://t.co/03lNpQiVYZ

"Let the young know they will never find a more interesting, more instructive book than the patient himself." – Giorgio Baglivi

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer. https://t.co/i3FMOCbyNg

If severe refractory SLE is defined as SLEDAI-2K≥10 despite steroids & immunosuppressives; Cohort of 3,744 SLE - 14% (578) had srSLE. Median SLEDAI-2K = 12, & decreased to 6 at 6m & 12m> < 25% achieved LLDAS & only 1% attained GC-free remission @ 12 mos https://t.co/7tehA27gyT https://t.co/yef4wCpqNf

• Prevalence and outcomes of a pilot definition of severe refractory systemic lup…

Emapalumab Approved for MAS in Still’s On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with https://t.co/431PQlzBsV

TNFi are relatively contraindicated in RA pts w/ #MS. Literature review suggests for pts w/ MS and RA, teriflunomide and anti-CD20 therapies are the most suitable, and Cladribine may also be considered https://t.co/gIVaJ7Kwn0 https://t.co/1ar0q2OnzB

• https://buff.ly/FE26mXw

Fibrosis in IgG4-related disease due to the overexpression of early growth response-1 (EGR-1) by Epithelial cells that facilitates tissue fibrosis https://t.co/AEaoucfT13 https://t.co/7UVQpkj3cn https://t.co/PuCjh5LQc5

• https://buff.ly/fnQ14E7
• https://buff.ly/94QmII9